June 10, 2022 -- Patient recruitment and retention are among the biggest challenges facing clinical research, particularly in studies targeting rare diseases that have a limited pool of patients, contends Clincierge CEO Scott Gray.
At the 2022 Biotechnology Innovation Organization (BIO) International Convention, Clincierge will release the results of an independent, institutional review board approved study commissioned by the support services company and conducted by Insight and Measurement, examining the patient experience in clinical trials of rare diseases.
Among the findings of the study: 95% of surveyed patients indicated that they seriously considered dropping out of a clinical trial due to challenges associated with travel. While 65% of patients said receiving reimbursements made it "a lot" easier to remain in a clinical trial, about 33% of patients indicated that it has taken a month or more to receive reimbursement during their participation in a trial.
"It's a huge issue so companies need to consider how do they improve their return on investment on conducting clinical trials by considering these human-social factors that surround the patients' lives," Gray told ScienceBoard.net.
Gray will moderate a June 13 panel at BIO 2022, "Participant Sensitivity: Amplifying the Voice of the Patient in Clinical Trials," on how patients' experiences impact clinical trials and the practical strategies for overcoming barriers to trial participation.
Watch the video below to learn more.